All In Biotech

Drug Trial Radar · NCT06309355

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

A Randomized, Placebo-controlled, Double-blind, Multi Center, Phase IIa Trial Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of Topical Ointment YR001 in Adult Patients With Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Jun 19, 2024

Primary completion

Nov 20, 2025

Study completion Nov 20, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • YR001 ointmentDrug

    The intervention is YR001 ointment on a range of body surface area for multiple topical administration

  • PlaceboOther

    The intervention is Placebo on a range of body surface area for multiple topical administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50.Time frame: Day1-Day 50

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Encore Medical Research -Boynton Beach

    Boynton Beach, Florida

  • Encore Medical Research-Hollywood

    Hollywood, Florida

  • Encore Medical Research-Weston

    Weston, Florida

  • DelRicht Research

    Baton Rouge, Louisiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.